Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH35995 in Healthy Adult Male Participants
NCT06517914Phase 1Active, not recruiting
- Sponsor
- Yuhan
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Gaucher disease type 3 comparing YH35995 with Placebo (2 arms). Primary endpoint: Treatment-emergent adverse events. Started Jul 2024; status: active, not recruiting.
02
Drugs
YH35995
03
Conditions
Gaucher disease type 3
Beyond the preview
Go deeper on NCT06517914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517914.